{"id":"https://openalex.org/W4387809802","doi":"https://doi.org/10.1016/j.annonc.2023.09.3080","title":"353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01","display_name":"353TiP Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01","publication_year":2023,"publication_date":"2023-10-01","ids":{"openalex":"https://openalex.org/W4387809802","doi":"https://doi.org/10.1016/j.annonc.2023.09.3080"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2023.09.3080","doi":"https://doi.org/10.1016/j.annonc.2023.09.3080","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.3080","pdf_url":"http://www.annalsofoncology.org/article/S0923753423039170/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.annalsofoncology.org/article/S0923753423039170/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087002800","display_name":"Snehal Sanjay Patel","orcid":"https://orcid.org/0000-0002-5002-7530","observed_orcids":["https://orcid.org/0000-0002-5002-7530"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Patel","raw_affiliation_strings":["Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Thompson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Thompson","raw_affiliation_strings":["Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Patel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Patel","raw_affiliation_strings":["Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040662689","display_name":"F. Joseph Daugherty","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F.J. Daugherty","raw_affiliation_strings":["Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical and Regulatory, Greenwich LifeSciences, Inc., Stafford, TX, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072850149","display_name":"Mothaffar Fahed Rimawi","orcid":"https://orcid.org/0000-0002-4284-5656","observed_orcids":["https://orcid.org/0000-0002-4284-5656"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Rimawi","raw_affiliation_strings":["Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Oncology, Baylor College of Medicine, Houston, TX, USA","institution_ids":["https://openalex.org/I181547552"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4060,"currency":"USD","value_usd":4060},"apc_paid":null,"fwci":0.1046,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.44766487,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"34","issue":null,"first_page":"S323","last_page":"S323"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gm-csf","display_name":"GM-CSF","score":0.9399999976158142},{"id":"https://openalex.org/keywords/her2-neu","display_name":"HER2/neu","score":0.8130000233650208},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9309999942779541},{"id":"https://openalex.org/keywords/residual-disease","display_name":"residual disease","score":0.6759999990463257},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.7910000085830688},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8859999775886536},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.8009999990463257},{"id":"https://openalex.org/keywords/immune-response","display_name":"immune response","score":0.39800000190734863},{"id":"https://openalex.org/keywords/peptide-vaccine","display_name":"peptide vaccine","score":0.47200000286102295},{"id":"https://openalex.org/keywords/recurrence-free-survival","display_name":"recurrence-free survival","score":0.4690000116825104}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9425346851348877},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6710593104362488},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6116347908973694},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6085972189903259},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5891222953796387},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5880874991416931},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5126282572746277},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.5099977254867554},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44870510697364807},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4311528205871582},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4283849596977234},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3810434341430664},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.1959954798221588},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.12022066116333008},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2023.09.3080","doi":"https://doi.org/10.1016/j.annonc.2023.09.3080","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.3080","pdf_url":"http://www.annalsofoncology.org/article/S0923753423039170/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2023.09.3080","doi":"https://doi.org/10.1016/j.annonc.2023.09.3080","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2023.09.3080","pdf_url":"http://www.annalsofoncology.org/article/S0923753423039170/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8500000238418579,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320316932","display_name":"Mersana Therapeutics","ror":"https://ror.org/05jyg6z06"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320318946","display_name":"Relay Therapeutics","ror":"https://ror.org/02bkgy413"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320321625","display_name":"Daiichi-Sankyo","ror":"https://ror.org/027y26122"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387809802.pdf","grobid_xml":"https://content.openalex.org/works/W4387809802.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1859326399","https://openalex.org/W2085650940","https://openalex.org/W1966127473","https://openalex.org/W2169836118","https://openalex.org/W2081991953","https://openalex.org/W2025729332","https://openalex.org/W1974781192","https://openalex.org/W2414325864","https://openalex.org/W2074965717","https://openalex.org/W2085830368"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-10T00:00:00"}